Acala Tech 100mg - Acalabrutinib Tablets

Price 5000.0 INR/ Unit

Get a Price/Quote

MOQ : 1 Unit

Acala Tech 100mg - Acalabrutinib Tablets Specification

Salt Composition
Acalabrutinib Tablets

About Acala Tech 100mg - Acalabrutinib Tablets

Background and Date of approval ACALABRUTINIB

Acalabrutinib is an anticancer medicine containing the active constituent acalabrutinib. It belongs to a class of drugs called Bruton's tyrosine kinase (BTK) inhibitors. Acalabrutinib was first approved by the U.S. Food and Drug Administration (FDA) on October 31, 2017, to treat adult patients with mantle cell lymphoma who have received at least one prior therapy. It was later approved by the FDA on August 17, 2020, for the treatment of adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.

Uses of ACALABRUTINIB

Acalabrutinib is used to treat mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL), and small lymphocytic lymphoma (SLL). MCL, CLL, and SLL are cancers of the white blood cells called lymphocytes that are part of the immune system.

How is ACALABRUTINIB administered?

Acalabrutinib is typically administered through injection by a healthcare provider. The specific method of administration may vary depending on the condition being treated and the healthcare provider's instructions. If a dose is missed, the patient should contact their healthcare provider for further instructions.

Side Effects of ACALABRUTINIB

Common side effects may include headache, diarrhea, fatigue, and muscle aches. Serious side effects may include bleeding, infections, heart rhythm problems, and lung inflammation. Acalabrutinib may also increase the risk of developing other types of cancer.

Tell us about your requirement